Acorda Therapeutics, Inc.
Case Number:
7:24-bk-22284
Court:
Nature of Suit:
Firms
- Baker McKenzie
- Carlton Fields
- Cravath Swaine
- Foley & Lardner
- Freshfields
- Hunton Andrews
- King & Spalding
- Klehr Harrison
- Lowenstein Sandler
- McDermott Will & Emery
- Paul Hastings
- Ropes & Gray
- Seward & Kissel
- Spencer Fane
- Squire Patton
- Tarter Krinsky
- Togut Segal
- Wilson Elser
Companies
- Acorda Therapeutics Inc.
- Biogen Inc.
- Catalent Inc.
- Cencora Inc.
- CVS Health Corp.
- Express Scripts Holding Co.
- Jabil Inc.
- Medco Health Solutions Inc.
- Nsight
- Nsight Inc.
- Oracle Corp.
- The Cigna Group
- Wilmington Trust Corp.
Sectors & Industries:
-
August 12, 2024
Byju's Dodges Dismissal, Crypto Updates, SunPower Filing
The U.S.-based affiliate of Indian educational technology giant Byju's avoided the dismissal of its Chapter 11 case in Delaware, a subpoena for cellphone records from former bankruptcy judge David R. Jones was quashed, and a $2 billion bankruptcy from a residential solar technology company was filed. This is the week in bankruptcy
-
August 07, 2024
Acorda Creditors' Ch. 11 Votes Count As Release Consent
A New York bankruptcy judge said Wednesday creditors' votes in favor of the Chapter 11 plan of Acorda Therapeutics constitute consent in granting third-party releases, overruling the position of the United States trustee that the Supreme Court's recent ruling in Purdue Pharma requires a separate agreement on releases.
-
June 18, 2024
Rite Aid, SVB Affiliates Among Top 2024 Ch. 11 Sales So Far
Branches of Rite Aid and Silicon Valley Bank, technology and biotech firms and a discount store chain were among the companies that attracted top dollar in the Chapter 11 auctions held during the first half of 2024.
-
June 11, 2024
Acorda Disclosures Lack Info On Releases, Say Creditors
Drugmaker Acorda Therapeutics Inc. faced objections to its disclosure statement from its creditors committee and the U.S. Trustee's Office, which said it failed to provide enough information about releases in the plan.
-
June 07, 2024
Acorda Therapeutics Gets OK On $185M Ch. 11 Sale To Merz
Drugmaker Acorda Therapeutics Inc. received a New York bankruptcy judge's approval Friday to complete a $185 million sale of its assets to a fellow pharmaceutical company, allowing Acorda to move ahead with a Chapter 11 plan to wind down its business.
-
May 03, 2024
Acorda Therapeutics Strikes Creditor Deal On Ch. 11 Loan
A New York judge on Friday gave final approval to Acorda Therapeutics' $60 million Chapter 11 financing package after hearing the drug developer and the lenders had resolved objections lodged by unsecured creditors.
-
April 04, 2024
Acorda Gets Interim OK For $60M DIP With $40M Rollup
Acorda Therapeutics Inc., a developer of drug treatments for neurological disorders, received on Thursday interim approval to access $10 million of a $60 million debtor-in-possession loan package from a group of prepetition noteholders.
-
April 04, 2024
Meet The Attys In Acorda Therapeutics' Ch. 11
Attorneys from Baker McKenzie LLP are representing Acorda Therapeutics in its Chapter 11 bankruptcy in New York as it moves toward a sale of its assets to another pharmaceutical company.
-
April 02, 2024
Acorda Therapeutics Hits Ch. 11, Plans $185M Drug Sale
Neurological disorders drugmaker Acorda Therapeutics Inc. filed for Chapter 11 protection in New York bankruptcy court, with plans to sell its assets to another pharmaceutical company for $185 million.